The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries – For Whom, by Whom and Where?
Kaan Kavaklı,
Canan Albayrak,
Bulent Antmen,
Selin Aytac,
Can Balkan,
Zuhre Kaya,
Alphan Kupesiz,
Vahap Okan,
Mehmet Sonmez,
Fahri Sahin,
Ekrem Unal,
Bulent Zulfikar,
Department of Pediatrics,
Division of Hematology,
Ege University,
Faculty of Medicine,
Department of Pediatrics,
Division of Hematology,
Ondokuz Mayıs University,
Faculty of Medicine,
Department of Pediatrics,
Division of Hematology,
Acıbadem University,
Faculty of Medicine,
Department of Pediatrics,
Division of Hematology,
Hacettepe University,
Faculty of Medicine,
Department of Pediatrics,
Division of Hematology,
Gazi University,
Faculty of Medicine,
Department of Pediatrics,
Division of Hematology,
Akdeniz University,
Faculty of Medicine,
Department of Internal Medicine,
Division of Hematology,
Gaziantep University,
Faculty of Medicine,
Department of Internal Medicine,
Division of Hematology,
Karadeniz Technical University,
Faculty of Medicine,
Department of Internal Medicine,
Division of Hematology,
Ege University,
Faculty of Medicine,
School of Health Sciences,
Division of Hematology,
Hasan Kalyoncu University,
Inherited Bleeding Disorders Center,
Istanbul University,
Oncology Institute
Clinical and Applied Thrombosis/Hemostasis
Published online on June 12, 2026
Clinical and Applied Thrombosis/Hemostasis, Volume 32, January-December 2026.
Hemophilia, a congenital deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B), leads to recurrent bleeding episodes that may cause progressive joint damage and long-term disability. Traditional management relies on intravenous factor ...